omeprazole; sodium bicarbonate · Azurity · NDA 213593
Konvomep
Earliest generic entry, as listed
1 Mar 2040
Blocked by patent: US 11771686. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11771686 | use U-623 | 1 Mar 2040 |
| US 10751333 | product | 16 Jul 2039 |
| US 11103492 | product | 16 Jul 2039 |
| US 11633478 | product | 16 Jul 2039 |
| US 11911473 | use U-624 | 16 Jul 2039 |
| US 11911473 | use U-623 | 16 Jul 2039 |
| US 12042539 | product | 16 Jul 2039 |
| US 12329752 | product | 16 Jul 2039 |
| US 12440566 | product | 16 Jul 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 213593-00110 Dec 2025
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213593 · 001 · RLD | for suspension, oral | 2MG/ML;84MG/ML | 1 Mar 2040 |